APA (7th ed.) Citation

Liu, Q., Tan, C., Yi, L., Wan, X., Peng, L., Li, J., . . . Zeng, X. (2021). Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer. Public Library of Science (PLoS).

Chicago Style (17th ed.) Citation

Liu, Qiao, Chongqing Tan, Lidan Yi, Xiaomin Wan, Liubao Peng, Jianhe Li, Xia Luo, and Xiaohui Zeng. Cost-effectiveness Analysis of Pembrolizumab Plus Chemotherapy as First-line Therapy for Extensive-stage Small-cell Lung Cancer. Public Library of Science (PLoS), 2021.

MLA (8th ed.) Citation

Liu, Qiao, et al. Cost-effectiveness Analysis of Pembrolizumab Plus Chemotherapy as First-line Therapy for Extensive-stage Small-cell Lung Cancer. Public Library of Science (PLoS), 2021.